24th BSMO annual meeting 2022
Friday 4 February 2022
10:00- 12:00 Breast cancer task force – chairs Kevin Punie & Michail Ignatiadis
10:00-10:35 Advanced HER2-positive breast cancer: treatment algorithm 2022 – Eline Naert, UZ Gent
10:35-11:10 Current and emerging treatment options in early and locoregionally advanced triplenegative breast cancer – Francois Duhoux, UCLouvain
11:10-11:45 Dissecting TNBC heterogeneity through molecular profiling and spatial transcriptomics – Christos Sotiriou, Institut Jules Bordet (MP4 file)
14:00-15:30 Molecular test in oncology – chairs Willem Lybaert
14:00-14:30 The BALLETT study and the NGS situation in Belgium – Brigitte Maes, Jessa Ziekenhuis
14:30-15:00 Molecular Tumor Board, pitfalls and practical issues – Kevin Punie, UZ Leuven
15:00-15:15 Clinical implications: reimbursement of drugs in lung cancer – Lore Decoster, UZ Brussel
15:15-15:30 Clinical implications: reimbursement of drugs in GI cancer – Wim Demey, AZ Klina Brasschaat and Joëlle Collignon, CHU-Sart-Tilman, Liège
16:00-17:30 Proffered papers by junior members – chairs Hans Prenen & Annemie Rutten
16:00-16:10 Detection of circulating tumor DNA (ctDNA) post neoadjuvant chemotherapy (NACT) using a personalized assay in patients (pts) with early breast cancer (EBC) is associated with disease relapse – Frederic Cailleux, Institut Jules Bordet
16:10-16:20 Microenvironment-mediated lipid metabolism reprogramming and anti-EGFR therapy resistance in head and neck squamous cell carcinoma – Valentin Van den Bossche, FATH, IREC, UCLouvain
16:20-16:30 PREDICT underestimates survival of patients (pts) with HER2-positive (HER2+) earlystage breast cancer (EBC) – Elisa Agostinetto, Institut Jules Bordet
16:30-16:40 Emotional Freedom Techniques as an effective strategy for treatment of selfreported cancer-related cognitive impairment in cancer survivors (EMOTICON) – Laura Tack, AZ Groeninge
16:40-16:50 Spatial organization of the immune microenvironment after neoadjuvant treatment of breast cancer – Noémie Thomas, Institut Jules Bordet
16:50-17:00 Cetuximab: An Effective Treatment of Vulvar Squamous Cell Carcinoma – Nourhan Lizziek, Saint George Hospital University Medical Center
17:00-17:10 Sjögren’s syndrome induced by immune checkpoint inhibitors: case report of two patients and review of the literature – Dan Truc Nguyen, CHU Ambroise Paré
17:10-17:20 Immune-related adverse events: A single-center retrospective analysis in a real-world scenario – Mireille Langouo, Institut Jules
Saturday 5 February 2022
08:30-09:30 “Supportive care” task force meeting – chairs Christel Fontaine & Jean Klastersky
08:30-08:41 Proposal of a new study in cardio-oncology – Berlinde Von Kemp, UZ Brussel
08:41-08:52 Teleprehabilitation for breast cancer pts prior surgery – Kenza Mostaqim, VUB
08:52-09:03 The role of EFT to treat fear for cancer relapse – Philip Debruyne and Laura Tack, AZ Groeninge
09:03-09:14 New BSMO guidelines concerning extravasation – Florence van Ryckeghem, azGlorieux
09:14-09:25 New BSMO guidelines concerning anemia – Caroline Lamot, AZ Nikolaas
09:25-09:30 Status of cancer pain survey and conclusions – Christel Fontaine, UZ Brussel
09:30-10:00 What you should not have missed in 2021 – Ahmad Hussein Awada, Institut Jules Bordet
10:00-10:30 Radiation oncology for the medical oncologist – Liv Veldeman, UZ Gent
11:00-11:30 BiTox – Sandrine Aspeslagh and Marthe Verhaert, UZ Brussel
11:30-12:00 Keynote lecture: head and neck cancer – Jean-Pascal Machiels, Cliniques universitaires Saint-Luc
12:00-12:10 Pfizer award – Improve the care and quality of life of rectal cancer patients after their treatment and their caregivers – Yves Vannieuwenhove and Eva Pape, UZGent